hATTR Compass Genetic Testing Program

Akcea Therapeutics and Ambry Genetics are partnering to offer confidential, no-cost genetic testing and confidential counseling to patients suspected of having or clinically diagnosed with hATTR amyloidosis through the hATTR Compass program.

To highlight the urgency around early genetic testing, Akcea developed the hATTR Compass Genetic Testing Video Series. These videos feature physician and patient perspectives on the hATTR Compass Program and highlight other patient resources available through hATTR Compass.

hATTR Compass is designed to:

  • Help accelerate or confirm the diagnosis of hATTR amyloidosis
  • Provide support and resources to patients, caregivers, and healthcare professionals throughout the genetic testing process
  • Empower patients and their healthcare providers to make the most informed decisions about their healthcare

The hATTR Compass Program is available for patients in the U.S. and Canada who are 18 years and older and have a family history of hATTR amyloidosis. If there is no family history, the patient must have at least two clinical symptoms or manifestations related to hATTR amyloidosis.

For more information and resources, please visit www.hATTRCompass.com.